Caprius, Inc. Announces 115% 2007 Revenue Growth.

HACKENSACK, N.J. -- Caprius, Inc. (OTCBB: CAPS) announced revenue for the year ended September 30, 2007 totaled $2,664,404 compared to $1,235,469 last year, an increase of approximately 115.6%. Revenue for the fourth quarter ended September 30, 2007 was $840,627, an increase of 109% compared to $401,967 in the same quarter last year and a 24% sequential increase compared to the third quarter ended June 30, 2007.

Dwight Morgan, President & CEO of Caprius, commented, "In 2007, we saw a considerable increase in the demand for our cost-efficient, safe and environmentally friendly solution for the on-site disposal of medical waste. This demand was driven by broader regulatory approval for the product, improved sales and distribution and word-of-mouth endorsements throughout the medical community that Caprius provides an economical and dependable solution. We also bolstered our domestic and international distribution capabilities by partnering with McKesson Medical-Surgical and Henry Schein, Inc., two of the leading medical distributors."

Mr. Morgan continued, "The customer base grew dramatically as we sold across a broader range of markets including dialysis clinics, surgical centers and hospitals. The number of SteriMed systems delivered in 2007 increased dramatically to over 60 units. Of particular note, during the year we worked closely with top dialysis companies to place units in clinics and further extended our reach into the small and medium sized dialysis chain market. Finally, the SteriMed Junior was placed into a highly anticipated shipboard trial with the U.S. Navy, as they look to develop a viable on-site medical waste management solution for the unique shipboard environment."

Mr. Morgan concluded, "As we head into 2008, our strong backlog of orders includes new as well as repeat customers, and spans a diverse range of customers in the U.S. and overseas. The increasing demand for our units, together with our recent financing, positions us well to capitalize on this market opportunity and scale our business to profitability."

These results are as reported in our recently filed Form 10-KSB.

About Caprius

Caprius, Inc. is a manufacturer of proprietary equipment for the on-site disinfection of infectious medical waste through its subsidiary, M.C.M. Environmental Technologies, Inc. The Company's innovative SteriMed technology simultaneously shreds and disinfects solid and liquid regulated medical waste, reducing the volume by up to 90% and rendering it harmless for disposal as ordinary waste. The SteriMed units are economical, compact, efficient and convenient, as well as environmentally friendly. The MCM patented technology offers an alternative to hauling and incinerating medical waste. Industry analysts estimate the medical waste market to be approximately $3 billion in the US and approximately $10 billion worldwide. More information on the Company and MCM can be found at www.caprius.com and www.mcmetech.com.

Safe Harbor Statement

This press release may contain forward-looking statements that involve risks and uncertainties. These statements refer to future plans, objectives, expectations and intentions. These statements may be identified by the use of words such as "anticipate," "believe," "intend," "plan," "expect" and other similar expressions. The Company's actual results could differ materially from those discussed in, or implied by, such forward-looking statements. You should also be aware of risks and uncertainties that, in the Company's view, could cause actual results to differ materially including changes related to regulatory and environmental approvals, manufacturing, operations, capital needs, technological advances by competitors and changes in health care reform, including reimbursement programs.

Certain information concerning economic trends and performance is based upon or derived from information provided by third-party consultants and other industry sources. While the Company believes that such information is accurate and that the sources from which it was obtained are reliable, it cannot guarantee the accuracy of such information, as it has not independently verified the assumptions on which projections of future trends and performance are based.